Liquid Biopsy Approaches for Cancer Characterization, Residual Disease Detection, and Therapy Monitoring
American Society of Clinical Oncology Educational Book · 2025-06 · 45 (3)
DOI: 10.1200/edbk-25-481114 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Society of Clinical Oncology Educational Book, 2025-06. Verfasst von Jacqueline V Aredo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA. Hauptthemen laut MEDLINE: Neoplasms, Neoplasm, Residual, Circulating Tumor DNA, Biomarkers, Tumor. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 163 Literaturangaben.
Abstract (Originalsprache)
Liquid biopsy encompasses a variety of molecular approaches to detect circulating tumor DNA (ctDNA) and has become a powerful tool in the diagnosis and treatment of solid tumors. Current applications include comprehensive genomic profiling for identifying targetable mutations and therapeutic resistance mechanisms, with emerging applications in minimal residual disease detection and treatment response monitoring. Increasingly, the potential for liquid biopsy in guiding treatment decisions is under active investigation through prospective clinical trials using ctDNA-adaptive interventions in patients with early-stage and metastatic cancers. Limitations arise on the basis of the sensitivity and feasibility of individual liquid biopsy assays; nonetheless, emerging technologies set the stage for improving these shortcomings. As the global oncology community continues to ascertain the clinical value of liquid biopsy across the continuum of patient care, this minimally invasive approach heralds a significant advancement in the promise of precision oncology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA.
- The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD.
- The Johns Hopkins Molecular Tumor Board, Johns Hopkins School of Medicine, Baltimore, MD.
- Huntsman Cancer Institute, University of Utah, Salt Lake City, UT.
- Division of Hematology and Oncology, Department of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL.
- Lung Cancer Precision Medicine Center of Excellence, Johns Hopkins University School of Medicine, Baltimore, MD.
Zitieren
APA
Aredo, J. V., Jamali, A., Zhu, J., Heater, N., Wakelee, H. A., Vaklavas, C., Anagnostou, V., & Lu, J. (2025). Liquid Biopsy Approaches for Cancer Characterization, Residual Disease Detection, and Therapy Monitoring. American Society of Clinical Oncology Educational Book, 45(3). https://doi.org/10.1200/edbk-25-481114
Vancouver
Aredo JV, Jamali A, Zhu J, Heater N, Wakelee HA, Vaklavas C, et al. Liquid Biopsy Approaches for Cancer Characterization, Residual Disease Detection, and Therapy Monitoring. American Society of Clinical Oncology Educational Book. 2025;45(3). doi:10.1200/edbk-25-481114
BibTeX
@article{Aredo2025,
author = {Aredo, Jacqueline V and Jamali, Amna and Zhu, Jessica and Heater, Natalie and Wakelee, Heather A and Vaklavas, Christos and Anagnostou, Valsamo and Lu, Janice},
title = {Liquid Biopsy Approaches for Cancer Characterization, Residual Disease Detection, and Therapy Monitoring},
journal = {American Society of Clinical Oncology Educational Book},
year = {2025},
volume = {45},
number = {3},
doi = {10.1200/edbk-25-481114}
}
EUVIMED